title: Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients.
authors.affiliation: Department of Hemato-oncology, Hôpital Saint-Louis, AP-HP, Paris, France.
authors.forename: Hélène
authors.initials: H
authors.lastname: Monjanel
authors.forename: Laure
authors.initials: L
authors.lastname: Deville
authors.forename: Caroline
authors.initials: C
authors.lastname: Ram-Wolff
authors.forename: Marie-Dominique
authors.initials: MD
authors.lastname: Venon
authors.forename: Patricia
authors.initials: P
authors.lastname: Franchi
authors.forename: Claire
authors.initials: C
authors.lastname: Benet
authors.forename: Eric
authors.initials: E
authors.lastname: de Kerviler
authors.forename: Marion
authors.initials: M
authors.lastname: Malphettes
authors.forename: Catherine
authors.initials: C
authors.lastname: Thieblemont
authors.forename: Pauline
authors.initials: P
authors.lastname: Brice
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy*; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D018796:Immunoconjugates; D000079963:Brentuximab Vedotin
keywords: Hodgkin lymphoma; anaplastic large-cell lymphoma; brentuximab vedotin; monoclonal antibody; primary refractory